Regulus Therapeutics Inc. (NASDAQ:RGLS) Files An 8-K Results of Operations and Financial Condition

Regulus Therapeutics Inc. (NASDAQ:RGLS) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

Story continues below

In Exhibit 99.1 attached to this report under the heading “Risk Factors—We may need to raise additional capital, which may not be available on acceptable terms, or at all”, we disclose that, as of June30, 2017, we had cash, cash equivalents and short-term investments of $40.1million. This financial result is preliminary and unaudited and may differ from what will be reflected in our condensed financial statements as of and for the quarter ended June30, 2017.

The information contained in Exhibit 99.1 attached to this report is being filed for the purpose of updating certain aspects of our publicly disclosed description of our business and risk factors.

Item 2.02 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.

Description

99.1 Company Disclosure

Forward-Looking Statements

Statements contained in this report regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with our expected ability to undertake certain activities and accomplish certain goals, the projected timeline of clinical development activities, and expectations regarding future therapeutic and commercial potential of our business plans, technologies and intellectual property related to microRNA therapeutics and biomarkers being discovered and developed by us.Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect.Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.These and other risks concerning our financial position and programs are described in additional detail in our filings with theSecurities and Exchange Commission, including under the caption “Risk Factors” in Exhibit 99.1 attached to this report.All forward-looking statements contained in this report speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


Regulus Therapeutics Inc. Exhibit
EX-99.1 2 d423592dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 COMPANY OVERVIEW We are a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class drugs targeting microRNAs to treat diseases with significant unmet medical need. We were formed in 2007 when Alnylam Pharmaceuticals,…
To view the full exhibit click here

About Regulus Therapeutics Inc. (NASDAQ:RGLS)

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

An ad to help with our costs